Literature DB >> 10982202

Clinical and biological findings in a case with 48-hour bipolar ultrarapid cycling before and during valproate treatment.

G Juckel1, U Hegerl, P Mavrogiorgou, J Gallinat, T Mager, P Tigges, S Dresel, A Schröter, G Stotz, I Meller, W Greil, H J Möller.   

Abstract

BACKGROUND: The rare cases of patients with 48-hour ultrarapid cycling allow close investigation of mood cycles in affective disorders, because rhythmic changes in psychopathologic state and biological parameters happen very precisely.
METHOD: A 67-year-old white man who had experienced bipolar 48-hour ultrarapid cycling (DSM-IV 296.80) for several years was studied without any medication and then again studied 4 weeks later during treatment with valproate (1800 mg/day).
RESULTS: Objective and self ratings revealed pronounced manic states 1 day and depressed states the following day, which were found to be accompanied by rhythmic fluctuations in behavior and electroencephalographic parameters, blood cortisol and growth hormone levels (both elevated on depressive days), and urinary metanephrine (dopamine metabolite) and norepinephrine levels (both elevated on manic days). Using single photon emission computed tomography, regional blood flow in the left thalamus was lower than in the right thalamus on the manic day, while symmetric perfusion of the thalamus was found on the depressive day. Under valproate treatment, the patient remitted completely, and significant rhythmic changes in most of the biological parameters were no longer detectable.
CONCLUSION: The biological findings in this patient with bipolar 48-hour ultrarapid cycling, which correspond to those in other types of affective disorders, suggest that disturbances in the diencephalon-pituitary axis may be especially correlated to pathologic changes of mood.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10982202     DOI: 10.4088/jcp.v61n0808

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  8 in total

Review 1.  Treating Circadian Rhythm Disruption in Bipolar Disorder.

Authors:  Alexandra K Gold; Gustavo Kinrys
Journal:  Curr Psychiatry Rep       Date:  2019-03-02       Impact factor: 5.285

Review 2.  The neurobiology of the switch process in bipolar disorder: a review.

Authors:  Giacomo Salvadore; Jorge A Quiroz; Rodrigo Machado-Vieira; Ioline D Henter; Husseini K Manji; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2010-05-04       Impact factor: 4.384

Review 3.  The Bech-Rafaelsen Mania Scale in clinical trials of therapies for bipolar disorder: a 20-year review of its use as an outcome measure.

Authors:  Per Bech
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 4.  Clinical research diagnostic criteria for bipolar illness (CRDC-BP): rationale and validity.

Authors:  S Nassir Ghaemi; Jules Angst; Paul A Vohringer; Eric A Youngstrom; James Phelps; Philip B Mitchell; Roger S McIntyre; Michael Bauer; Eduard Vieta; Samuel Gershon
Journal:  Int J Bipolar Disord       Date:  2022-10-13

5.  Increased Asymmetric Perfusion of the Cerebral Cortices and Thalamus Indicates Individuals at Risk for Bipolar Disorder: A Family Cohort Single Photon Emission Computed Tomography Neuroimaging Study.

Authors:  Mary McLean; Theodore A Henderson; Dan G Pavel; Phil Cohen
Journal:  Front Psychiatry       Date:  2022-05-10       Impact factor: 5.435

Review 6.  Noradrenaline plays a critical role in the switch to a manic episode and treatment of a depressive episode.

Authors:  Masatake Kurita
Journal:  Neuropsychiatr Dis Treat       Date:  2016-09-20       Impact factor: 2.570

Review 7.  Animal models for bipolar disorder: from bedside to the cage.

Authors:  Dominik K E Beyer; Nadja Freund
Journal:  Int J Bipolar Disord       Date:  2017-10-13

8.  Dosage-related nature of escitalopram treatment-emergent mania/hypomania: a case series.

Authors:  Yasunari Yamaguchi; Sohei Kimoto; Takeshi Nagahama; Toshifumi Kishimoto
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-17       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.